

# The Genetics of Pancreatic Cancer

Dagan Efrat<sup>1,2</sup> and Gershoni-Baruch Ruth<sup>1,3</sup>

<sup>1</sup>*Institute of Human Genetics, Rambam Health Care Campus, Haifa,*

<sup>2</sup>*Department of Nursing, the Faculty of Social Welfare and Health Sciences,  
University of Haifa,*

<sup>3</sup>*The Ruth and Bruce Rapoport Faculty of Medicine,  
Technion-Institute of Technology, Haifa,  
Israel*

## 1. Introduction

Globally, pancreatic cancer is considered a rare cause of cancer. More than 250,000 new cases, equivalent to 2.5% of all forms of cancer, were diagnosed in 2008 worldwide (Ferlay et al., 2008, 2010). Pancreatic adenocarcinoma currently represents the fourth most common cancer causing death in the United States and in most developed countries (Jemal et al., 2009, 2011). Despite advances in medical science, the overall prognosis of pancreatic cancer remains poor and five years survival is only 4% (Jemal et al., 2006). Those diagnosed early, with tumor limited to the pancreas, display a 25-30% five years survival following surgery (Ryu et al., 2010).

It has been suggested that it takes at least 10 years from tumor initiation to the development of the parental clone and another five years to the development of metastatic subclones, with patients dying within two years thereafter, on average (Costello & Neoptolemos, 2011). Given the limited treatment options there has been considerable focus on clinical and molecular harbingers of early disease. A mechanism for early detection and for early intervention remains to be elaborated. Current research is focused on the discovery and the development of diagnostic bio markers that can unveil pancreatic cancer in its early stages. Deciphering and understanding the genetics of sporadic and hereditary pancreatic cancer remains a fundamental milestone.

Based on family aggregation and family history of pancreatic disease, it is estimated that around 10% of cases diagnosed with pancreatic cancer host a hereditary germ line mutation (Lynch et al., 1996; Hruban et al., 1998). Furthermore, it has been observed that pancreatic cancer occurs in excess of expected frequencies, in several familial cancer syndromes, which are associated with specific germ-line mutations. The best characterized include hereditary breast-ovarian cancer syndrome ascribed to mutations in BRCA1/2 genes, especially BRCA2; familial pancreatic and breast cancer syndrome due to mutations in PALB2 gene; familial isolated pancreatic cancer caused by mutations in PALLD encoding palladin; and familial multiple mole melanoma with pancreatic cancer (FAMMM-PC) attributed to

mutations in CDKN2A. Other hereditary cancer syndromes demonstrating increased hereditary risk for pancreatic cancer, yet with less significance, include hereditary non-polyposis colorectal syndrome - Lynch syndrome and Li-Fraumeni syndrome which is caused by mutations in p53 gene.

The identification of individuals at risk for pancreatic cancer would aid in targeting those who might benefit most from cancer surveillance strategies and early detection (Brentnall et al., 1999). This chapter describes the cutting edge data related to the genetics of sporadic and hereditary pancreatic cancer subdivided according to 'genes' function.

## **2. Oncogenes**

### **2.1 KRAS gene (MIM 190070)**

Recent studies have shown that the KRAS oncogene on chromosome 12p is activated by point mutations in approximately 90% of pancreatic cancers tumors, and these mutations involve codon 12 most commonly, and codons 13 and 61 thereafter (Caldas & Kern, 1995). The RAS protein produced by wild-type KRAS binds GTPase-activating protein and regulates cell-cycle progression. Mutations in KRAS constitute the earliest genetic abnormalities underlying the development of pancreatic neoplasms (Maitra et al., 2006; Feldmann et al., 2007). KRAS may thus be a promising bio marker for early detection of curable non-invasive pancreatic neoplasia (Maitra et al., 2006).

### **2.2 BRAF gene (MIM 164757)**

The BRAF gene maps to chromosome 7q and takes part in the RAF-MAP signaling pathway, critical in mediating cancer causing signals in the RAS corridor (Calhoun et al., 2003). BRAF mutations have been described in about 15% of all human cancers, including pancreatic cancer (Davies et al., 2002). The BRAF gene is activated by oncogenic RAS, leading to cooperative mutual effects in cells responding to growth factor signals. BRAF and KRAS appear to be alternately mutated in pancreatic cancers; thus, pancreatic cancers with KRAS gene mutations do not harbor BRAF gene mutations and vice versa (Maitra et al., 2006).

### **2.3 PALLD gene (MIM 608092)**

Palladin RNA is over-expressed in tissues from both precancerous dysplasia and pancreatic adenocarcinoma in familial and sporadic pancreatic disease. The mutated gene is assumingly, best detected in very early precancerous dysplastic tissue, heralding neoplastic transformation before the overarching of genetic instability, underlying cancer, has occurred. Palladin is a component of actin-containing microfilaments that control cell shape, adhesion and contraction and is associated with myocardial infarction and pancreatic cancer. Palladin is most probably a proto-oncogene (Pogue-Geile et al., 2006).

#### **2.3.1 Familial pancreatic cancer associated PALLD gene (MIM 164757)**

Few families with isolated pancreatic cancer of early onset and high penetrance have been identified (Lynch et al., 1990; Brentnall et al., 1999; Banke et al., 2000; Hruban et al., 2001;

Meckler et al., 2001). Genomewide linkage screen of a family, noted as 'family X', has shown significant linkage to chromosome 4q32-34 (Eberle et al., 2002). Pogue-Geile et al. (2006) later found a mutation, inducing a proline (hydrophobic) to serine (hydrophilic) amino acid change (P239S), in a highly conserved region of the gene encoding palladin (PALLD), segregating in all affected family members and absent in unaffected family members. Zogopoulos et al. (2007) identified this same mutation (P239S) in one of 84 (1.2%) patients with familial and early-onset pancreatic cancer and in one of 555 controls (0.002%). No evidence for palladin mutations in 48 individuals with familial pancreatic cancer was recorded by Klein et al. (2009). Further investigation is warranted in order to confirm the pathogenicity of mutations in PALLD.

## 2.4 Other oncogenes

*AKT2* (MIM 164731) - It has been suggested that the *AKT2* oncogene, on chromosome 19q, contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. Cheng et al., (1996) demonstrated that the *AKT2* oncogene is over expressed in approximately 10-15% of pancreatic carcinomas. *AKT2* encodes a protein belonging to a subfamily of serine/threonine kinases.

*AIB1* (MIM 601937) - *AIB1* gene, on chromosome 20q, is amplified in as many as 60% of pancreatic cancers (Anzick et al., 1997; Calhoun et al., 2003; Aguirre et al., 2004). Altered *AIB1* expression may contribute to the development of steroid-dependent cancers. It has also been reported that amplification of a localized region on the long arm of chromosome 8 is commonly seen in pancreatic cancers, and this amplification corresponds to the oncogenic transcription factor *CMYC* (MIM 190080) (Aguirre et al., 2004).

In addition to these genes, numbers of amplicons, amplified from DNA fragments, have been identified in pancreatic cancers by using gene chip technologies (Aguirre et al., 2004). Employing array comparative genomic hybridization (CGH) technology, a high resolution analysis of genome-wide copy number aberrations, permits to identify over expression of DNA fragments in tumor transformed pancreatic cells. Understanding the mechanisms underlying the development of pancreatic cancer may aid target early detection, gene-specific therapies and thereby improve prognosis.

## 3. Tumor suppressor genes

In pancreatic invasive adenocarcinoma, *CDKN2A/INK4A*, *TP53*, and *DPC4/SMAD4/MADH4* are commonly inactivated.

### 3.1 *CDKN2A/INK4A* gene (MIM 600160)

The *CDKN2A* gene on chromosome 9p21 encodes proteins that control two critical cell cycle regulatory pathways, the p53 (*TP53*) pathway and the retinoblastoma (*RB1*) pathway. Through the use of shared coding regions and alternative reading frames, the *CDKN2A* gene produces 2 major proteins: p16(*INK4*), which is a cyclin-dependent kinase inhibitor checkpoint, and p14(*ARF*), which binds the p53-stabilizing protein *MDM2* (Robertson and Jones, 1999). P16 inhibits cyclin D1 by binding to the cyclin-dependent kinases *Cdk4* and *Cdk6* thereby causing G1-S cell-cycle arrest (Schutte et al., 1997). Loss of p16 function,

consequent to several different mechanisms, including homozygous deletion, intragenic mutation and epigenetic silencing by gene promoter methylation, is seen in approximately 90% of pancreatic cancers (Caldas et al., 1994; Schutte et al., 1997; Ueki et al., 2000). As a bystander effect, homozygous deletions of the CDKN2A/INK4A gene can also delete both copies of the methylthio-adenosine phosphorylase (MTAP) gene, whose product is essential for the salvage pathway of purine synthesis. In about a third of pancreatic cancers co-deletion of the MTAP and CDKN2A/INK4A genes is observed (Hustinx et al., 2005).

This observation has a potential therapeutic significance, since chemotherapeutic regimes selectively targeted to cells demonstrating loss of Mtap function are currently available.

### **3.1.1 Familial Atypical Multiple Mole Melanoma – Pancreatic Cancer (FAMMM-PC) syndrome (MIM 606719)**

The association between mutations in p16 (CDKN2A) and familial pancreatic cancer was previously noted by Caldas et al. (1994) and others (Liu et al., 1995; Whelan et al., 1995; Schutte et al., 1997). Further evidence for a plausible role of CDKN2A in pancreatic cancer was provided by Whelan et al. (1995) who described a kindred at risk for pancreatic cancers, melanomas, and additional types of tumors, co-segregating with a CDKN2A mutation. CDKN2A mutations were detected individuals with pancreatic cancer from melanoma families (Goldstein et al., 1995). Later, Lynch et al., 2002, coined the term hereditary FAMMM-PC syndrome to describe families with both melanoma and pancreatic cancers. Although rare, the life time risk of CDKN2A carriers, to develop pancreatic cancer and melanoma was calculated to be 58% and 39%, respectively (McWilliams et al., 2010). Basically, CDKN2A is a small gene, containing 3 coding exons. However, lack of founder mutations impedes the screening of families at risk in the clinical setting.

### **3.2 TP53 gene (MIM 191170)**

The TP53 gene on chromosome 17p undergoes bi-allelic inactivation in approximately 50–75% of pancreatic cancers, almost always subject to the combination of an intragenic mutation and the loss of the second wild-type allele (Redston et al., 1994). The transcription factor p53 responds to diverse cellular stresses formulated to regulate target genes participating in G1-S cell cycle checkpoint, maintenance of G2-M arrest, cell cycle arrest, apoptosis, senescence and DNA repair (Redston et al., 1994). There is emerging evidence to suggest that loss of p53 function may contribute to the genomic instability observed in pancreatic cancers (Hingorani et al., 2005); and that TP53 gene mutations constitute late events in pancreatic cancer progression (Maitra et al., 2003).

#### **3.2.1 Li- Fraumeni syndrome (MIM 151623)**

Li-Fraumeni syndrome is a rare, clinically and genetically heterogeneous, inherited cancer syndrome caused by germline mutations in TP53. Li-Fraumeni syndrome is characterized by autosomal dominant inheritance and early onset of tumors, rather multiple tumors in one individual and multiple affected family members. In contrast to other inherited cancer syndromes, which are predominantly characterized by site-specific cancers, Li-Fraumeni syndrome presents with a variety of tumor types. The most common types are soft tissue sarcomas and osteosarcomas, breast cancer, brain tumors, leukemia, and adrenocortical

carcinoma (Li et al., 1988). Several families with Li-Fraumeni syndrome presenting with pancreatic cancer were occasionally described (Lynch et al., 1985; Casey et al., 1993).

### 3.3 Deleted in pancreatic carcinoma 4 (DPC4) gene (MIM 600993)

About 90% of human somatic pancreatic carcinomas show allelic loss at 18q. Hahn et al. (1996) reported the identification of a putative tumor suppressor gene, namely, Deleted in Pancreatic Carcinoma 4 or DPC4 (also known as SMAD4/MADH4) on chromosome 18q21.1. Loss of Dpc4 protein function interferes with intracellular signaling cascades leading to decreased growth inhibition and uncontrolled proliferation. SMAD4 plays a pivotal role in signal transduction of the transforming growth factor beta superfamily cytokines by mediating transcriptional activation of target genes. Immunohistochemical labeling for Dpc4 protein expression mirrors DPC4/SMAD4/MADH4 gene status with rare exceptions, and like TP53, loss of Dpc4 expression is a late genetic event in pancreatic carcinoma and is observed in about 30% of progression lesions (Feldmann et al., 2007).

Genome-wide association studies (GWAS) have provided evidence that a person's risk of developing pancreatic cancer is influenced by multiple common disease alleles with small effects (Low et al., 2010; Petersen et al., 2010). Further research is required to evaluate the epidemiological input of these markers to the development of pancreatic cancer and their availability for early detection (Costello & Neoptolemos, 2011). Other tumor-suppressor genes are targeted at low frequency in pancreatic cancer. These genes provide a significant insight into the molecular mechanism that underlines pancreatic cancers, and may serve as therapeutic targets in the early stages of pancreatic cancer.

## 4. Genome-maintenance genes

Several gene ensembles, that play a role in caring for genome stability, were found to be mutated in pancreatic cancer, more so, in familial rather than sporadic cancer, including familial pancreatic cancer. BRCA2 is with no doubt the prominent gene in this category.

### 4.1 BRCA1/2 genes (MIM 113705/600185)

*BRCA1* - The gene product of BRCA1, functions in a number of cellular pathways that maintain genomic stability, including DNA damage-induced cell cycle checkpoint activation and arrest, DNA damage repair, protein ubiquitination, chromatin remodeling, as well as transcriptional regulation and apoptosis (see for example review by Wu et al., 2010). BRCA1 forms several distinct complexes through association with different adaptor proteins, and each complex assemble in a mutually exclusive manner (Wang et al., 2009).

*BRCA2* - BRCA2 plays a key role in recombinational DNA repair, maintenance of genomic integrity and resistance to agents that damage DNA or collapse replication forks. The role of BRCA2 is best understood during DNA double-strand break repair (see for example Schlacher et al., 2011) as it co-localizes with PALB2 gene in nuclear foci, thereby promoting its stability in nuclear structures and enabling its recombinational repair and checkpoint functions (Xia et al., 2006).

Both BRCA1 and BRCA2 have transcriptional activation and seem to be mutually interrelated.

Traditionally BRCA1 and BRCA2 were classified as tumor suppressor genes. Nowadays, BRCA1 and BRCA2 are rather cataloged as 'caretaker' genes that act, amongst other, as nucleotide-excision-repair (NER) genes (Kinzler and Vogelstein, 1997). While, inactivated 'gatekeepers', namely, tumor suppressor genes, promote tumor initiation directly, the inactivation of caretaker genes leads to genetic instability resulting in increased mutations in other genes, including gatekeepers. Once a tumor is initiated by inactivation of a caretaker gene, it may progress rapidly due to an accelerated rate of mutations in other genes that directly control cell birth or death. Consistent with this hypothesis, mutations in BRCA1 and BRCA2 are rarely found in sporadic cancers, and the risk of cancer arising in people with BRCA somatic mutations is relatively low.

#### 4.1.1 Hereditary breast-ovarian cancer syndrome

Since the late nineties of the 20<sup>th</sup> century, excess of pancreatic cancer cases was documented in families with hereditary breast-ovarian cancer syndrome, traditionally linked to BRCA1/2 genes. Several studies have shown high BRCA2 mutation carrier frequencies in pancreatic cancer patients, reaching 10-20%, more so in Jewish Ashkenazi compared to non-Jewish pancreatic cancer patients (Teng et al., 1996; Ozcelik et al., 1997; Slater et al., 2010), with greater penetrance for males over females (Risch et al., 2001; Murphy et al., 2002; McWilliams et al., 2005; Dagan, 2008; Dagan et al., 2010; Ferrone et al., 2009). BRCA1 mutations are less often associated with pancreatic cancer compared to BRCA2 mutations (Al-Sukhni et al., 2008; Dagan et al., 2010). Mutations within the OCCR-ovarian cancer-cluster region of the BRCA2 gene in exon 11 frequently cause either/or pancreatic cancer, ovarian cancer and other type of cancers (Risch et al., 2001; Thompson et al., 2001).

The distinction between gatekeepers and caretakers genes has important practical and theoretical ramifications. Tumors that have defective caretaker genes are expected to respond favorably to therapeutic agents that induce the type of genomic damage that is normally detected or repaired by the particular caretaker gene involved.

Poly (ADP-ribose) polymerase (PARP) inhibitors have raised recent excitement as to their deleterious effect on BRCA1 or BRCA2 associated ovarian, breast or pancreatic cancer cells. If either PARP or BRCA function remains intact, a cell will continue to survive. Thus, inhibiting PARP should not affect the non-cancerous cells that contain one functional copy of BRCA. Loss of both functions, however, is incompatible with life (Bryant et al., 2005; Helleday et al., 2005; Drew et al., 2011). With this in mind, this class of agents has the potential to potentiate cytotoxic therapy without increased side effects. Acting as sole agents, they are able to exterminate cancer cells with DNA repair defects. The genomic instability of tumor cells allows PARP inhibitors to selectively target tumor cells rather than normal cells. PARP proteins inhibitors have gained supremacy as ideal anticancer agents (Weil & Chen, 2011) and may promise better prognosis in pancreatic, ovarian and breast cancer due to hereditary mutations in BRCA1/2.

#### 4.2 Partner and localizer of BRCA2 (PALB2) gene (MIM 610355)

PALB2 maps to chromosome 16p12 (Xia et al., 2006; Reid et al., 2007; Xia et al., 2007). Differential extraction showed that BRCA2 and PALB2 colocalize in S-phase foci and are associated with stable nuclear structures. As PALB2 is critical for the function of BRCA2 as

regards DNA repair, it should be considered, in principle, as a caretaker gene. Like BRCA2, PALB2 participates in DNA damage response and both genes collectively cooperate allowing BRCA2 to escape the effects of proteasome-mediated degradation (Reid et al., 2007; Xia et al., 2007).

#### 4.2.1 Familial pancreatic cancer associated PALB2

Germline mutations in PALB2 have been identified in approximately 1-2% of familial breast cancer and 3-4% of familial pancreatic cancer cases (Slater et al., 2010; Casadei et al., 2011; Hofstatter et al., 2011). Three pancreatic cancer patients out of 96, with a positive family history of pancreatic cancer were found to harbor a PALB2 germline deletion of 4 basepairs, that was absent in 1084 control samples (Jones et al., 2009; Rahman et al., 2007). PALB2 appears to be the second most commonly mutated gene implicated in hereditary pancreatic cancer after BRCA2 (Jones et al., 2009).

#### 4.3 Hereditary non-polyposis colon syndrome – HNPCC (MIM 120435)

Pancreatic cancer was infrequently described in families with hereditary non-polyposis colon cancer (Lynch et al., 1985; Miyaki et al., 1997). HNPCC subdivided into Lynch I, primarily affecting the colon, Lynch II mainly targeting extra colonic organs including the pancreas and Muir-Torre syndrome. HNPCC is a genetically heterogeneous disease, with most mutations detected in MSH2 and MLH1 genes.

*MSH2 (MIM 609309)* - The microsatellite DNA instability that is associated with alteration in the MSH2 gene in hereditary nonpolyposis colon cancer and several forms of sporadic cancer is thought to arise from defective repair of DNA replication errors. MSH2 has a direct role in mutation avoidance and microsatellite stability in human cells (Fishel et al., 1994).

*MLH1 (MIM 609310)* - Similarly to MSH2, MLH1 gene encodes a protein involved in the identification and repair of DNA mismatch errors. The identification of germline mutations in *MLH1* and *MSH2* was rapidly followed by the discovery of other human genes that encode proteins involved in the mismatch repair (MMR) complex (see review by Lynch et al., 2009).

### 5. Synopsis

Pancreatic cancer is of the most lethal of all human malignancies caused by inherited and acquired (somatic) mutations. The poor prognosis of pancreatic cancer (Jemal et al., 2006) warrants early detection of asymptomatic individuals, at high risk, using imaging methods and molecular analyses and thereby providing them with a chance for better survival (Goggins et al., 2000). Understanding the complex genetic mechanisms underlying the development of pancreatic cancer, as depicted in this chapter, may conduit medical science in the path that will ultimately lead to early detection, tailored treatment and consequently better prognosis for this incurable disease.

Although, novel mechanisms, sprout on the horizon, could be exploited for early detection, as depicted by the KRAS detection technology, it seems that most pancreatic neoplasms in the general population will remain undetectable before invasive cancer develops. However, the recognition of early genetic somatic changes can advocate for presymptomatic chemo or

surgical prevention schemes that may alleviate those with pre cancerous neoplasms before an invasive cancer had a chance to develop. This farfetched undertaking is already underway.

Although, pancreatic cancer is basically sporadic, about 10% of the patients harbor a germline mutation. It seems that BRCA2 is the major susceptibility gene contributing to hereditary pancreatic cancer, especially in populations segregating founder mutations, namely, Ashkenazi Jews, Icelandic (Thorlacius et al., 1996; Dagan, 2008; Dagan et al., 2010) and others. Beyond this, pancreatic cancer patients and family members at risk should follow the standard recommendations, as regards genetic counseling and diagnosis that befits hereditary breast-ovarian cancer. Thus, the follow-up surveillance schemes for BRCA1/2 mutation carriers have to focus, in addition to the standard recommendations, on early detection of pancreatic cancer.

Deciphering the precise functional role of genes, involved in the development of pancreatic cancer, may open new and exciting targets for chemotherapy. The recognition that BRCA1/2 and PARP proteins combine forces in maintaining genomic stability and DNA damage repair, as well as transcriptional regulation and apoptosis, has prompted the clinical development of PARP inhibitors. It has been recently shown that PARP inhibitors are selectively toxic to human cancer cell lines with BRCA1/2 mutations. Furthermore, these agents may have a therapeutic potential in tumors with defects in homologous recombinant DNA repair (HRR) system (Drew et al., 2010). Clinical trials of PARP inhibitors, especially with olaparib, in BRCA1/2 mutated cancer patients confirm their potential therapeutic effect. Further studies are required to address the many questions regarding safety and efficacy in the clinical setting (Fong et al., 2009).

## 6. References

- Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, Leo C, Zhang Y, Zhang J, Gans JD, Bardeesy N, Cauwels C, Cordon-Cardo C, Redston MS, DePinho RA, Chin L (2004) High-resolution characterization of the pancreatic adenocarcinoma genome. *Proc Natl Acad Sci USA*. 101:9067-9072.
- Al-Sukhni W, Rothenmund H, Eppel Borgida A, Zogopoulos G, O'Shea A-M, Pollett A, Gallinger S (2009) Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. *Hum Genet*. 124:271-278.
- Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan X-Y, Sauter G, Kallioniemi O-P, Trent JM, Meltzer PS (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science* 277:965-968.
- Banke MG, Mulvihill JJ, Aston CE (2000) Inheritance of pancreatic cancer in pancreatic cancer-prone families. *Med Clin North Am*. 84:677-690, x-xi.
- Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 434:913-917.
- Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. *Ann Intern Med*. 131:247-255.

- Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat Genet.* 8:27-32.
- Caldas C, Kern SE (1995). K-ras mutation and pancreatic adenocarcinoma. *Int J Pancreatol.* 18:1-6.
- Casadei S, Norquist BM, Walsh T, Stray SM, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC (2011) Contribution to Familial Breast Cancer of Inherited Mutations in the BRCA2-interacting Protein PALB2. *Cancer Res.* 71:2222-2229.
- Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, Hempen PM, Hilgers W, Yeo CJ, Hruban RH, Kern SE (2003) BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. *Am J Pathol.* 163:1255-1260.
- Casey G, Yamanaka Y, Freiss H, Kobrin MS, Lopez ME, Buchler M, Beger HG, Korc M (1993) p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. *Cancer Lett.* 69:151-160.
- Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR (1996) Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. *Proc Natl Acad Sci U S A.* 93:3636-3641.
- Costello E, Neoptolemos JP (2011) New insights for early intervention and detection. *Nat Rev Gastroenterol Hepatol.* 8:71-73.
- Dagan E (2008) Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer. *Genet Test.* 12:267-271.
- Dagan E, Epelbaum R, Gershoni-Baruch R (2010) BRCA1/2 mutations in pancreatic cancer patients and their clinical characteristics. *Am Soc Human Genet.* 60<sup>th</sup> Annual Meeting. WA DC. Poster presentation No. 595.
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. *Nature* 417:949-954.
- Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ (2011) Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. *J Natl Cancer Inst.* 103:334-346.
- Eberle MA, Pfützner R, Pogue-Geile KL, Bronner MP, Crispin D, Kimmey MB, Duerr RH, Kruglyak L, Whitcomb DC, Brentnall TA (2002) A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. *Am J Hum Genet.* 70:1044-1048.

- Feldmann G, Beaty R, Hruban RH, Maitra A (2007). Molecular genetics of pancreatic intraepithelial neoplasia. *J Hepatobiliary Pancreat Surg.* 14:224-32.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, International Agency for Research on Cancer, 2010. <http://globocan.iarc.fr>.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 127:2893-2917.
- Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME (2009) BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. *J Clin Oncol.* 20:433-438.
- Fishel R, Ewel A, Lee S, Lescoe MK, Griffith J (1994) Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. *Science* 266:1403-1405.
- Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med.* 361:123-134.
- Goggins M, Canto M, Hruban R (2000) Can we screen high-risk individuals to detect early pancreatic carcinoma? *J Surg Oncol.* 74:243-248.
- Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, Tucker MA (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. *N Engl J Med.* 333:970-974.
- Hahn SA, Schutte M, Hoque TMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 271:350-354.
- Helleday T, Bryant HE, Schultz N (2005) Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. *Cell Cycle* 4:1176-1178.
- Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell* 7:469-483.
- Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N (2011) PALB2 mutations in familial breast and pancreatic cancer. *Fam Cancer* 10:225-231.
- Hruban RH, Petersen GM, Ha PK, Kern SE (1998) Genetics of pancreatic cancer. From genes to families. *Surg Oncol Clin N Am.* 7:1-23.
- Hruban RH, Canto MI, Yeo CJ (2001) Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer. *Dig Dis.* 19:76-84.
- Hustinx SR, Leoni LM, Yeo CJ, Brown PN, Goggins M, Kern SE, Hruban RH, Maitra A (2005) Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. *Mod Pathol.* 18:959-63.


- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. *CA Cancer J Clin.* 56:106-130.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. *CA Cancer J Clin.* 59:225-249.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global Cancer Statistics. *CA Cancer J Clin.* 2011;61:69-90
- Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC-H, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 324: 217.
- Kinzler KW, Vogelstein B (1997) Gatekeepers and caretakers. *Nature* 386:761-763.
- Klein AP, Borges M, Griffith M, Brune K, Hong SM, Omura N, Hruban RH, Goggins M (2009) Absence of deleterious palladin mutations in patients with familial pancreatic cancer. *Cancer Epidemiol Biomarkers Prev.* 18:1328-1330.
- Li FP, Fraumeni JR, Jr Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. *Cancer Res.* 48:5358-5362.
- Liu Q, Yan Y-X, McClure M, Nakagawa H, Fujimura F, Rustgi AK (1995) MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. *Oncogene* 10: 619-622.
- Low SK, Kuchiba A, Zembutsu H, Saito A, Takahashi A, Kubo M, Daigo Y, Kamatani N, Chiku S, Totsuka H, Ohnami S, Hirose H, Shimada K, Okusaka T, Yoshida T, Nakamura Y, Sakamoto H (2010) Genome-wide association study of pancreatic cancer in Japanese population. *PLoS ONE* 5:e11824.
- Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF (1985) Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. *Brit J Cancer* 52:271-273.
- Lynch HT, Fitzsimmons ML, Smyrk TC, Lanspa SJ, Watson P, McClellan J, Lynch JF (1990) Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. *Am J Gastroenterol.* 85:54-60.
- Lynch HT, Smyrk T, Kern SE, Hruban RH, Lightdale CJ, Lemon SJ, Lynch JF, Fusaro LR, Fusaro RM, Ghadirian P (1996) Familial pancreatic cancer: a review. *Semin Oncol.* 23:251-275.
- Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, Liu L, Knezetic J, Lassam NJ, Goggins M, Kern S (2002) Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. *Cancer* 94:84-96.
- Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin Genet.* 76:1-18.
- Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, Yeo CJ, Hruban RH (2003) Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. *Mod Pathol.* 16:902-912.

- Maitra A, Kern SE, Hruban RH (2006) Molecular pathogenesis of pancreatic cancer. *Best Pract Res Clin Gastroenterol.* 20:211-226.
- McWilliams RR, Rabe KG, Olswold C, De Andrade M, Petersen GM (2005) Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. *Cancer* 104:388-394.
- McWilliams RR, Wieben ED, Rabe KG, Pedersen KS, Wu Y, Sicotte H, Petersen GM (2010). Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. *Eur J Hum Genet.* Dec 8.
- Meckler KA, Brentnall TA, Haggitt RC, Crispin D, Byrd DR, Kimmey MB, Bronner MP (2001) Familial fibrocystic pancreatic atrophy with endocrine cell hyperplasia and pancreatic carcinoma. *Am J Surg Pathol.* 25:1047-1053.
- Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T (1997) Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. *Nature Genet.* 17:271-272.
- Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH, Kern SE (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. *Cancer Res.* 62: 3789-3793.
- Ozcelik H, Schmocker B, Di Nicola N, Shi X-H, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S, Redston M (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. *Nature Genet.* 16: 17-18.
- Petersen GM et al. (2010) A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. *Nature Genet.* 42:224-228.
- Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Downen S, Otey CA, Crispin DA, George RD, Whitcomb DC, Brentnall TA (2006) Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. *PLoS Med.* 3: e516.
- Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, The Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nature Genet.* 39: 165-167.
- Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. *Cancer Res.* 54:3025-3033.
- Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. *Nature Genet.* 39: 162-164.
- Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL., Fan I, Wong B, Narod SA (2001) Prevalence and

- penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet.* 68:700-710.
- Robertson KD, Jones PA (1999) Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. *Oncogene* 18:3810-3820.
- Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A (2010) Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. *Pancreatology* 10:66-73.
- Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M (2011) Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11. *Cell* 145:529-542.
- Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. *Cancer Res.* 57:3126-3130.
- Slater EP, Langer P, Fendrich V, Habbe N, Chaloupka B, Matthäi E, Sina M, Hahn SA, Bartsch DK (2010) Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. *Fam Cancer* 9:335-343.
- Teng DH-F, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, David T, Ha PC, Kehrer R, Jammulapati S, Chen Q, Offit K, Skolnick MH, Tavtigian SV, Jhanwar S, Swedlund B, Wong AKC, Kamb A (1996) Low incidence of BRCA2 mutations in breast carcinoma and other cancers. *Nature Genet.* 13: 241-244.
- Thompson D, Easton D, Breast Cancer Linkage Consortium (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. *Am J Hum Genet.* 68:410-419.
- Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. *Nature Genet.* 13:117-122.
- Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma. *Cancer Res.* 60:1835-1839.
- Wang B, Hurov K, Hofmann K, Elledge SJ (2009) NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. *Genes Dev.* 23:729-739.
- Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast cancer. *Curr Probl Cancer* 35:7-50.
- Whelan AJ, Bartsch D, Goodfellow PJ (1995) Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. *New Eng J Med.* 333: 975-977.
- Wu J, Lu LY, Yu X (2010) The role of BRCA1 in DNA damage response. *Protein Cell* 1:117-123.
- Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Molec Cell* 22: 719-729.
- Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter J P (2007)

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. *Nature Genet.* 39: 159-161.

Zogopoulos G, Rothenmund H, Eppel A, Ash C, Akbari MR, Hedley D, Narod SA, Gallinger S (2007) The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreatic cancer. *Hum Genet.* 121: 635-637.



## **Pancreatic Cancer - Clinical Management**

Edited by Prof. Sanjay Srivastava

ISBN 978-953-51-0394-3

Hard cover, 312 pages

**Publisher** InTech

**Published online** 28, March, 2012

**Published in print edition** March, 2012

This book covers pancreatic cancer risk factors, treatment and clinical procedures. It provides an outline of pancreatic cancer genetic risk factors, biomarkers and systems biology for the better understanding of disease. As pancreatic cancer suffers from lack of early diagnosis or prognosis markers, this book encompasses stem cell and genetic markers to identify the disease in early stages. The book uncovers the rationale and effectiveness of monotherapy and combination therapy in combating the devastating disease. As immunotherapy is emerging as an attractive approach to cease pancreatic cancer progression, the present book covers various aspects of immunotherapy including innate, adaptive, active, passive and bacterial approaches. Management of anesthesia during surgery and pain after surgery has been discussed. Book also takes the reader through the role of endoscopy and fine needle guided biopsies in diagnosing and observing the disease progression.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Dagan Efrat and Gershoni-Baruch Ruth (2012). The Genetics of Pancreatic Cancer, Pancreatic Cancer - Clinical Management, Prof. Sanjay Srivastava (Ed.), ISBN: 978-953-51-0394-3, InTech, Available from: <http://www.intechopen.com/books/pancreatic-cancer-clinical-management/the-genetics-of-pancreatic-cancer>

# **INTECH**

open science | open minds

### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.